Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Adrenocortical carcinoma (ACC) is a rare disease with a poor response to chemotherapy. Cisplatin is the most widely investigated drug in the treatment of ACC and in vitro studies have indicated activity of taxanes. The objectives of this study were to evaluate the efficacy and toxicity of cisplatin combined with docetaxel as first-line treatment of advanced ACC.
Original languageEnglish
JournalB J C
Volume108
Issue number10
Pages (from-to)1994-7
Number of pages4
ISSN0007-0920
DOIs
Publication statusPublished - 28 May 2013

    Research areas

  • Adrenal Cortex Neoplasms, Adrenocortical Carcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Disease Progression, Female, Humans, Male, Middle Aged, Survival Analysis, Taxoids, Treatment Outcome, Young Adult

ID: 42241587